Elevated Serum MCP-2 and TARC Associated With Increased Risk of Death in Guamanian ALS Patients

Overview

Journal Eur J Neurol

Publisher Wiley

Specialty Neurology

Date 2025 Feb 25

PMID 39996599

Authors

Risana N Chowdhury

Musab A Azam

Suhaib A Azam

Shteynman Lana

Erin N Culver

Ralph M Garruto

Katherine Wander

Affiliations

Soon will be listed here.

Abstract

Background: This study explores the relationship between inflammation and longevity in a high-incidence focus of amyotrophic lateral sclerosis (ALS) in post-WWII Guam. Characteristics of this focus include the sudden appearance of the disease in high numbers and the unusually long lifespan (without medical interventions) seen in some cases. We used bio-banked specimens to evaluate the relationship between serum immunoregulators and survival time.

Methods: We evaluated sera from 69 Guam ALS cases collected within 2 years of symptom onset by NIH researchers from 1950 to 1983 for 11 immunoregulators via ELISA (CRP, eotaxin-1, RANTES, IL-6, IL-8, IL-10, IFN-γ, IP-10, MCP-1, MCP-2 and TARC). Factor analysis identified two factors responsible for ~68% of the variation in the data. We estimated Cox proportional hazards models to identify immunoregulators associated with time to death.

Results: Each 10-unit increase in factor 2 cytokines (MCP-2 and TARC) was associated with a 38% increase in the risk of death (HR: 1.38; 95% CI: 1.19, 1.65; p: 0.00).

Discussion: Like sporadic ALS cases worldwide, inflammation is associated with a shortened lifespan in Guamanian ALS; more specifically, our findings suggest serum levels of MCP-2 and TARC at onset may predict disease duration. Further investigation is needed to determine the role of these immunoregulators in disease prognosis and as targets for diagnostic and therapeutic interventions.

References

Pronto-Laborinho A, Pinto S, Gromicho M, Pereira M, Swash M, de Carvalho M . Interleukin-6 and amyotrophic lateral sclerosis. J Neurol Sci. 2019; 398:50-53. DOI: 10.1016/j.jns.2019.01.026. View

Garruto R, Yanagihara R, Gajdusek D . Disappearance of high-incidence amyotrophic lateral sclerosis and parkinsonism-dementia on Guam. Neurology. 1985; 35(2):193-8. DOI: 10.1212/wnl.35.2.193. View

Fernandez A, Guenegou L, Corcia P, Bailly N . The effect of social support on the emotional well-being of people with amyotrophic lateral sclerosis: Exploring the mediating role of spirituality. Palliat Support Care. 2024; :1-8. DOI: 10.1017/S1478951524000610. View

Masrori P, Van Damme P . Amyotrophic lateral sclerosis: a clinical review. Eur J Neurol. 2020; 27(10):1918-1929. PMC: 7540334. DOI: 10.1111/ene.14393. View

HOFFMAN P, Robbins D, Gibbs Jr C, Gajdusek D, Garruto R, Terasaki O . Histocompatibility antigens in amyotrophic lateral sclerosis and parkinsonism-dementia on Guam. Lancet. 1977; 2(8040):717. DOI: 10.1016/s0140-6736(77)90525-6. View

HOFFMAN P, Robbins D, Nolte M, Gibbs Jr C, Gajdusek D . Cellular immunity in Guamanians with amyotrophic lateral sclerosis and Parkinsonism-dementia. N Engl J Med. 1978; 299(13):680-5. DOI: 10.1056/NEJM197809282991302. View

Lunetta C, Lizio A, Maestri E, Sansone V, Mora G, Miller R . Serum C-Reactive Protein as a Prognostic Biomarker in Amyotrophic Lateral Sclerosis. JAMA Neurol. 2017; 74(6):660-667. PMC: 5822215. DOI: 10.1001/jamaneurol.2016.6179. View

Kurland L, MULDER D . Epidemiologic investigations of amyotrophic lateral sclerosis. I. Preliminary report on geographic distribution, with special reference to the Mariana Islands, including clinical and pathologic observations. Neurology. 1954; 4(5):355-78. DOI: 10.1212/wnl.4.5.355. View

HOFFMAN P, Robbins D, Gibbs Jr C, Gajdusek D . Immune function among normal Guamanians of different age. J Gerontol. 1983; 38(4):414-9. DOI: 10.1093/geronj/38.4.414. View

10.

Chowdhury R, Armato A, Culver E, Shteynman L, Kurien C, Cradin B . Quantitative and qualitative analysis of stability for 16 serum immunoregulators over 50 freeze-thaw cycles. Am J Hum Biol. 2024; 36(9):e24087. DOI: 10.1002/ajhb.24087. View

11.

Pare B, Lehmann M, Beaudin M, Nordstrom U, Saikali S, Julien J . Misfolded SOD1 pathology in sporadic Amyotrophic Lateral Sclerosis. Sci Rep. 2018; 8(1):14223. PMC: 6155098. DOI: 10.1038/s41598-018-31773-z. View

12.

Yanagihara R, Garruto R, Gajdusek D . Epidemiological surveillance of amyotrophic lateral sclerosis and parkinsonism-dementia in the Commonwealth of the Northern Mariana Islands. Ann Neurol. 1983; 13(1):79-86. DOI: 10.1002/ana.410130117. View

13.

HOFFMAN P, Robbins D, Oldstone M, Gibbs Jr C, Gajdusek D . Humoral immunity in Guamanians with amyotrophic lateral sclerosis and parkinsonism-dementia. Ann Neurol. 1981; 10(2):193-6. DOI: 10.1002/ana.410100210. View

14.

Chio A, Logroscino G, Hardiman O, Swingler R, Mitchell D, Beghi E . Prognostic factors in ALS: A critical review. Amyotroph Lateral Scler. 2009; 10(5-6):310-23. PMC: 3515205. DOI: 10.3109/17482960802566824. View

15.

Zhao W, Beers D, Hooten K, Sieglaff D, Zhang A, Kalyana-Sundaram S . Characterization of Gene Expression Phenotype in Amyotrophic Lateral Sclerosis Monocytes. JAMA Neurol. 2017; 74(6):677-685. PMC: 5822209. DOI: 10.1001/jamaneurol.2017.0357. View

16.

Guo J, Yang X, Gao L, Zang D . Evaluating the levels of CSF and serum factors in ALS. Brain Behav. 2017; 7(3):e00637. PMC: 5346523. DOI: 10.1002/brb3.637. View

17.

Chun C, Lee J, Bothwell M, Nghiem P, Smith A, Mack D . Human Motor Neurons Elicit Pathological Hallmarks of ALS and Reveal Potential Biomarkers of the Disease in Response to Prolonged IFNγ Exposure. J Neurosci. 2024; 44(16). PMC: 11026347. DOI: 10.1523/JNEUROSCI.1787-23.2024. View

18.

Su X, Simmons Z, Mitchell R, Kong L, Stephens H, Connor J . Biomarker-based predictive models for prognosis in amyotrophic lateral sclerosis. JAMA Neurol. 2013; 70(12):1505-11. DOI: 10.1001/jamaneurol.2013.4646. View

19.

Tortelli R, Zecca C, Piccininni M, Benmahamed S, DellAbate M, Barulli M . Plasma Inflammatory Cytokines Are Elevated in ALS. Front Neurol. 2020; 11:552295. PMC: 7691268. DOI: 10.3389/fneur.2020.552295. View

20.

Figlewicz D, Garruto R, Krizus A, Yanagihara R, Rouleau G . The Cu/Zn superoxide dismutase gene in ALS and parkinsonism-dementia of Guam. Neuroreport. 1994; 5(5):557-60. DOI: 10.1097/00001756-199401000-00006. View